Optimising malignant melanoma management in Europe
EUMelaReg collects health information to improve care and treatment for patients with skin cancer
Sustaining and fostering collaboration between academia and industry
for the collection of baseline, treatment and outcome data of representative samples of malignant melanoma patients of major European countries.
Building the largest and quickest melanoma registry in the world
EUMelaReg collects real-world data on melanoma patients throughout Europe and integrates them in a data warehouse.

Patients with NMSC – a registry-based cohort study

EUMelaReg has started a registry-based cohort study and presented an e-poster at EADO 2023 on “Modern Treatment Usage and Outcome of Patients with Advanced Non-Melanoma Skin Cancer (NMSC) – a Registry Based Cohort Study.”

Among NMSC, basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC) are the predominant histologic subtypes. Real-world data systematically recorded in registries are limited. Many cancer databases do not register NMSCs at all. For patients with advanced NMSC, the EUMelaReg consortium (EMR) introduced a registry for NMSC across Europe. The aim of this registry is to collect real-world data of the available tumor and treatment patterns of advanced NMSC patients at a European level. Data of the EMR NMSC-Registry can be used for specific analyses regarding drugs, availability, and affordability of various treatments for different patient populations, data on health-related resource utilization, and patient outcomes. It is of importance to have a comprehensive picture on various treatments, or non-treatment strategies across Europe.

If you are interested in participating in the NMSC study, please contact office@eumelareg.org. For more detailed information please visit https://beta.clinicaltrials.gov/study/NCT05741073